NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 197 filers reported holding NEVRO CORP in Q4 2019. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,150,000 | -90.5% | 67,600 | -83.5% | 0.39% | -78.2% |
| Q4 2021 | $33,176,000 | -46.1% | 409,230 | -22.7% | 1.80% | -32.1% |
| Q3 2021 | $61,592,000 | -1.3% | 529,230 | +40.6% | 2.66% | +6.6% |
| Q2 2021 | $62,392,000 | +131.0% | 376,330 | +141.2% | 2.49% | +139.3% |
| Q4 2020 | $27,012,000 | -73.5% | 156,046 | -78.7% | 1.04% | -74.4% |
| Q3 2020 | $101,825,000 | -19.1% | 730,977 | -30.7% | 4.08% | -22.8% |
| Q2 2020 | $125,934,000 | -28.1% | 1,054,103 | -39.9% | 5.28% | -29.6% |
| Q1 2020 | $175,227,000 | +27.4% | 1,752,620 | +49.8% | 7.49% | +52.6% |
| Q4 2019 | $137,531,000 | +67.7% | 1,170,080 | +22.7% | 4.91% | +58.3% |
| Q3 2019 | $82,000,000 | +3.0% | 953,820 | -22.3% | 3.10% | +0.4% |
| Q2 2019 | $79,594,000 | +395.5% | 1,227,730 | +377.7% | 3.09% | +375.8% |
| Q1 2019 | $16,064,000 | +165.8% | 256,990 | +65.4% | 0.65% | +243.4% |
| Q4 2018 | $6,044,000 | -75.1% | 155,410 | -63.9% | 0.19% | -86.2% |
| Q1 2016 | $24,241,000 | – | 430,877 | – | 1.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
| Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
| PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
| Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
| Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
| Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
| K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
| Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
| Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
| ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |